Compositions and methods for delivering lypophilic agents to dental pulp and for enhancing dentin production

Patent metadata

Field	Value
Publication number	US-11260103-B2
Application number	US-201916669340-A
Country	US
Kind code	B2
Filing date	Oct 30, 2019
Priority date	Dec 29, 2014
Publication date	Mar 1, 2022
Grant date	Mar 1, 2022

Abstract

Methods and compositions are provided for enhancing dentin production, and for delivering a lipophilic agent to pulp tissue of a tooth of an individual. In some cases, a subject method includes a step of administering to the pulp of a tooth of an individual, a Wnt stimulating composition that includes a Wnt stimulator agent, at a dose sufficient to enhance the production of dentin by the pulp. In some cases, a subject method includes a step of contacting exposed dentin of a tooth with a composition that includes a lipophilic agent inserted in the non-aqueous phase of a lipid structure (e.g., whereby the lipophilic agent penetrates the dentin to the underlying pulp tissue). Kits are also provided for practicing the methods of the disclosure.

First claim

What is claimed:

1. A method for enhancing dentin production, the method comprising:
(a) providing a tissue from a subject;
(b) contacting the tissue with liposomal Wnt3A, wherein the liposomal Wnt3A comprises a Wnt3A protein inserted into a non-aqueous phase of a lipid structure, thereby forming a Wnt3A-modified tissue; and
(c) administering the Wnt3A-modified tissue to a tooth of the subject.

2. The method according to claim 1 , wherein the Wnt3A protein is human Wnt3A.

3. The method according to claim 1 , wherein the Wnt3A protein has an amino acid sequence of SEQ ID NO: 19.

4. The method according to claim 1 , wherein the lipid structure comprises a size range of from 0.03 to 0.2 micron.

5. The method according to claim 1 , wherein the tissue is derived from dental pulp.

6. The method according to claim 1 , wherein the tissue is derived from bone marrow.

7. The method according to claim 1 , wherein the tissue provided from the subject is from the tooth to which the Wnt3A-modified tissue is administered.

8. The method according to claim 1 , wherein the tissue provided from the subject is from a different tooth of the subject than that to which the Wnt3A-modified tissue is administered.

9. The method according to claim 1 , wherein the Wnt3A-modified tissue is present in an amount sufficient to activate stem cells, progenitor cells, or a combination thereof in the tissue.

10. The method according to claim 1 , wherein the Wnt3A-modified tissue is present in an amount sufficient to reduce apoptosis of a dental pulp tissue in the tooth of the subject.

11. The method according to claim 1 , wherein the Wnt3A-modified tissue is administered to dental pulp tissue within the tooth.

12. The method according to claim 1 , wherein administering the Wnt3A-modified tissue increases the number of differentiated odontoblasts in the tooth.

13. The method according to claim 1 , wherein the Wnt3A-modified tissue promotes secretion of dentin matrix from odontoblasts in the tooth.

14. The method according to claim 1 , wherein the Wnt3A-modified tissue further comprises a pharmaceutically acceptable carrier.

15. The method according to claim 1 , wherein the Wnt3A-modified tissue is administered as a single administration.

16. The method according to claim 1 , wherein the Wnt3A-modified tissue is administered as part of a series of administrations.

17. The method according to claim 1 , wherein the subject is a human.

18. The method according to claim 1 , wherein the method is performed as part of a dental procedure.

19. The method according to claim 18 , wherein the dental procedure is a deep dental restoration.

20. The method according to claim 19 , wherein the deep dental restoration comprises placement of an amalgam, composite, or crown within the tooth.

Assignees

• Univ Leland Stanford Junior

Inventors

• Helms Jill
• Hunter Daniel L

Classifications

• A61K38/18

  Growth factors; Growth regulators · CPC title

• A61K38/17 Primary

  from animals; from humans {(enzyme inhibitors A61K38/005)} · CPC title

• A61P1/02

  Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K9/08

  Solutions {(composition of solutions A61K47/00)} · CPC title